The Global Landscape of Stem Cell Clinical Trials

Li, Matthew; Atkins, Harold L.; Bubela, Tania

doi:10.2217/rme.13.80

Cited by 143 publications

(103 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the increasing of clinic trials based in MSC could let us understand better the effect of them in vivo and this will open new scenes to strengthen and valid clinic trials of medicine regenerative a great scale [65,[78][79][80][81]. This could be a solution by the world health problems that DM2, its complications and other kinds or disease do [82].…”

Section: Discussionmentioning

confidence: 99%

Transcendence of Medicine Regenerative Strategies in the Treatment for Diabetic Foot Ulcers

Díaz-García¹,

Benítez-Arvizu²

2016

J Cancer Diagn

View full text Add to dashboard Cite

The Diabetes Mellitus type 2 and one of its complications, the diabetic foot ulcer (DFU), are a great problem of public health that affects millions of people around the world. Due to its complexity, DFUs treatment and handling are expensive and complex. In addition, amputations of lower limbs and death are relatively frequent because conventional treatment cannot avoid them. In other hand, the use of growth factors, 3D scaffolds and mesenchymal stem cells, called regenerative medicine (RM), have created new perspectives about the treatment of this kind of injuries. The RM has demonstrated favorable clinical outcomes not only in the case of DFUs, so that, this new medicine area promises to become an important tool that supports or substitutes to conventional treatment in cases of tissue or organic damage caused by the different chronic and traumatic diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcendence of Medicine Regenerative Strategies in the Treatment for Diabetic Foot Ulcers

Díaz-García¹,

Benítez-Arvizu²

2016

J Cancer Diagn

View full text Add to dashboard Cite

show abstract

“…To overcome these limitations, non-integrating adenovirus, sendai virus, episomal vector or completely DNAfree techniques have been developed [64][65][66][67], with the first in-human iPSC clinical trial taking place in 2014 [68]. The successful implantation of iPSC-derived retinal pigment epithelium cells into a patient with age-related macular dystrophy was reported; however, the trial was prematurely suspended when it was found that the second patient's differentiated cells contained multiple mutations [60].…”

Section: Induced Pscsmentioning

confidence: 99%

Augmentation of Musculoskeletal Regeneration: Role for Pluripotent Stem Cells

2018

View full text Add to dashboard Cite

The rise in the incidence of musculoskeletal diseases is attributed to an increasing ageing population. The debilitating effects of musculoskeletal diseases, coupled with a lack of effective therapies, contribute to huge financial strains on healthcare systems. The focus of regenerative medicine has shifted to pluripotent stem cells (PSCs), namely, human embryonic stem cells and human-induced PSCs, due to the limited success of adult stem cell-based interventions. PSCs constitute a valuable cell source for musculoskeletal regeneration due to their capacity for unlimited self-renewal, ability to differentiate into all cell lineages of the three germ layers and perceived immunoprivileged characteristics. This review summarizes methods for chondrogenic, osteogenic, myogenic and adipogenic differentiation of PSCs and their potential for therapeutic applications.

show abstract

“…For example, referring to the current practice of using stem cells isolated from one tissue to treat disease or injury in a different tissue, the ISSCR's scare list states, "Thus, it is unlikely that a single cell type can be used to treat a multitude of unrelated diseases involving different tissues or organs" and "How and where the cells are put back into your body matters, and some clinics inject cells into places where they are not normally present and do not belong [2]." Yet, more than half of approved clinical trials are designed to evaluate just this hypothesis that stem cells may confer healing properties to heterologous tissues [5].…”

Section: Not So Different Treatmentsmentioning

confidence: 99%